Recent developments in the treatment of hypertriglyceridemia

Current Atherosclerosis Reports

Volumn 1, Issue 1, 1999, Pages 31-37

  Duriez, Patrick ^a   Fruchart, Jean Charles ^a  

^a INSERM   (France)

Author keywords

Bezafibrate; Bezafibrate Infarction Prevention; Coronary Artery Disease Death; Gemfibrozil; Secondary Prevention Trial

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID;

BLOOD; CORONARY ARTERY DISEASE; HUMAN; HYPERTRIGLYCERIDEMIA; REVIEW;

ANTILIPEMIC AGENTS; BEZAFIBRATE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; FATTY ACIDS, OMEGA-3; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA;

EID: 0033157034     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-999-0047-1     Document Type: Article

References (41)

1. Kannel WB, Castelli WP, Gordon T, et al.: Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med 1971, 74:1–12.
2. Stamler J, Wentworth D, Neaton JD: Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986, 256:2823–2828. DOI: 10.1001/jama.256.20.2823
3. Stampfer MJ, Colditz GA, Willett WC, et al.: Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses’ health study. N Engl J Med 1991, 325:756–762. DOI: 10.1056/NEJM199109123251102
4. Smith GD, Shipley MJ, Marmot MG, et al.: Plasma cholesterol concentration and mortality. The Whitehall Study. JAMA 1992, 267:70–76. DOI: 10.1001/jama.267.1.70
5. Gordon DJ, Probstfield JL, Garrison RJ, et al.: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79:8–15.
6. Hodis HN, Mack WJ, Azen SP, et al.: Triglyceride-and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994, 90:42–49.
7. Assmann G, Schulte H: Role of triglycerides in coronary artery disease: lessons from the Prospective Cardiovascular Munster Study. Am J Cardiol 1992, 70:10H-13H. DOI: 10.1016/0002-9149(92)91084-H
8. Manninen V, Tenkanen L, Koskinen P, et al.: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992, 85:37–45.
9. Austin MA: Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991, 11:2–14.
10. Bhatnagar D: Lipid-lowering drugs in the management of hyperlipidaemia. Pharmacol Ther 1998, 79:205–230. DOI: 10.1016/S0163-7258(98)00018-7
11. Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta- analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3:213–219. DOI: 10.1097/00043798-199604000-00014
12. Jeppesen J, Hein HO, Suadicani P, et al.: Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998, 97:1029–1036.
13. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383–1389.
14. Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301–1307. DOI: 10.1056/NEJM199511163332001
15. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994, 89:1333–1445.
16. Caslake MJ, Packard CJ, Series JJ, et al.: Plasma triglyceride and low density lipoprotein metabolism. Eur J Clin Invest 1992, 22:96–104.
17. Gardner CD, Fortmann SP, Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996, 276:875–881. DOI: 10.1001/jama.276.11.875
18. Sacks FM, Moye LA, Davis BR, et al.: Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998, 97:1446–1452.
19. Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237–1245. DOI: 10.1056/NEJM198711123172001
20. Frick MH, Syvänne M, Nieminen MS, et al.: Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lipid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997, 96:2137–2143.
21. Canner PL, Berge KG, Wenger NK, et al.: Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245–1255. DOI: 10.1016/S0735-1097(86)80293-5
22. Pierce LR, Wysowski DK, Gross TP: Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990, 264:71–75. DOI: 10.1001/jama.264.1.71
23. Schaefer EJ, Gregg RE, Ghiselli G, et al.: Familial apolipoprotein E deficiency. J Clin Invest 1986, 78:1206–1219.
24. Syvänne M, Nieminen MS, Frick MH, et al.: Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Circulation 1998, 98:1993–1999.
25. Rubins HB: Veterans Affairs-High Density Lipoprotein Cholesterol Intervention Trial (VA-HIT). Scientific Sessions “American Heart Association” Dallas, November 11th 1998. Plenary Session XII Late Breaking Clinical Trials. 1998.
26. de Faire U, Ericsson CG, Hamsten A, et al.: Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Drugs Exp Clin Res 1995, 21:105–124.
27. de Faire U, Ericsson CG, Grip L, et al.: Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Eur Heart J 1996, 17 (suppl):37–42.
28. Ericsson CG, Nilsson J, Grip L, et al.: Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). Am J Cardiol 1997, 80:1125–1129. DOI: 10.1016/S0002-9149(97)00626-7
29. Ruotolo G, Ericsson CG, Tettamanti C, et al.: Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998, 32:1648–1656. DOI: 10.1016/S0735-1097(98)00442-2
30. Goldbourt U, Brunner D, Behar S, et al.: Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study. Eur Heart J 1998, 19 (suppl): H42-H47.
31. Ericsson CG, Hamsten A, Nilsson J, et al.: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996, 347:849–853. DOI: 10.1016/S0140-6736(96)91343-4
32. Kaplinsky E, Brunner D: The bezafibrate infarction prevention (BIP) study results [abstract]. XXth Congress of the European Society of Cardiology Vienne: 1998, August 22–August 26.
33. Staels B, Dallongeville J, Auwerx J, et al.: Mechanism of action of fibrates on lipid and lipoprotein metabolism [In Process Citation]. Circulation 1998, 98:2088–2093.
34. Leaf A, Weber PC: Cardiovascular effects of n-3 fatty acids. N Engl J Med 1988, 318:549–557. DOI: 10.1056/NEJM198803033180905
35. Harris WS: Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res 1989, 30:785–807.
36. von Schacky C, Weber PC: Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest 1985, 76:2446–2450.
37. von Schacky C, Fischer S, Weber PC: Long-term effects of dietary marine omega-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans. J Clin Invest 1985, 76:1626–1631. DOI: 10.1172/JCI112147
38. Late Breaking clinical trials II: coronary artery disease. Polyunsaturated fatty acids (PUFA) but not vitamin E improve prognosis in patients with myocardial infarction [abstract]. The GISSI-prevention trial. American Congress of Cardiology 1999, 48th Scientific Session:March 7–March 10th.
39. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al.: Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996, 275:128–133. DOI: 10.1001/jama.275.2.128
40. Stein EA, Lane M, Laskarzewski P: Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998, 81:66B-69B. DOI: 10.1016/S0002-9149(98)00041-1
41. Zambon D, Ros E, Rodriguez-Villar C, et al.: Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation. Metabolism 1999, 48:47–54 DOI: 10.1016/S0026-0495(99)90009-4